Bull and Bear

Bull and Bear

Verdict: Watchlist — the Q4 FY26 print in May 2026 is days away, and pre-positioning at 97x trailing into a credibility-impaired, pledge-encumbered, illiquid micro-cap when the resolver is observable in weeks is hard to justify. The Bear's case rests on structural facts management already conceded — FY27 ambition reset from 14% to 8–9% EBITDA, FY26 revenue walked from ₹1,800 cr toward ₹1,500 cr, and 10 of 12 quantified promises since IPO missed or reset. The Bull's case is mechanical and largely outside management's control — palm oil reversion, insurance recoveries, and Modasa Phase II — and Q3 FY26's 8% EBITDA print is genuine evidence the recovery is not just rhetoric. The decisive tension is whether FY24's 12% EBITDA was a steady state or an IPO-disclosure peak built on inventory and capex management; only a clean Q4 FY26 print can answer it. Until that print lands, the institutional move is to wait, not to anchor on either ₹500 or ₹200.

Bull Case

Bull's price target: ₹500 over 12–18 months, anchored to a peer-relative multiple — FY27 normalized EBITDA at 11% on ₹2,000 cr revenue → ~₹140 cr PAT → ~₹11.2 EPS at 45x (still a 30% discount to Bikaji's 65x to allow for the size and quality gap). The primary catalyst is the Q4 FY26 earnings print (May 2026): EBITDA margin ≥9% on revenue ≥₹400 cr, with concurrent insurance reconciliation against the ₹174 cr cover. The Bull's own disconfirming signal is a Q4 FY26 EBITDA below 8% on a clean (ex-recovery) basis, or cumulative insurance settlement under ₹70 cr through FY27 — either tells the Bull that FY23–24's 12–14% margin band was a peak built on inventory and capex management, not a structural mean.

Bear Case

Bear's downside target: ₹200 (–28% from ₹277) over 12–18 months, applying a 25x cycle-mid multiple to FY24 normalized EPS of ₹7.99. Cross-checks converge in a ₹180–200 range: FY27 guided ~₹6 EPS × 30x = ₹180; Bikaji-parity 65x on FY26 trailing of ~₹3 = ₹195. The primary trigger is the Q4 FY26 EBITDA print in May-2026 — Q3 FY26 printed 7.6% with insurance recoveries flowing above the line, and an 8%-or-lower clean print opens the next round of consensus cuts and re-tests the FY27 reset. The Bear's own cover signal is two consecutive clean quarters of EBITDA ≥11% with no exceptional/insurance tailwind, AND Modasa gross margin holding 27%+, AND non-Gujarat revenue growing 35%+ on an un-fire-distorted base — that combination would validate FY24's 12% as a structural mean and pull normalized EPS toward ₹10–12.

The Real Debate

Verdict

Watchlist. The Bear carries more structural weight: a credibility ledger (10 of 12 missed/reset promises, FY27 ambition halved on margin), a 9.72% promoter pledge into 0.06%-of-mcap daily liquidity, and a 97x trailing multiple on a fire-distorted base together describe a stock pricing a Bikaji-class recovery management has serially walked back. The single most important tension is margin trajectory — cycle or reset — and the Bear has the larger weight of evidence that pre-fire FY25 was already drifting below guide. The Bull could still be right: palm oil has normalized, Modasa Phase II is operational, ₹35–40 cr of insurance recoveries plausibly remain, and Q3 FY26 already printed 8% — a clean Q4 FY26 ≥9% on revenue ≥₹400 cr would validate the entire mean-reversion thesis and force a peer-relative re-rate. The verdict flips to Lean Long if Q4 FY26 prints ≥9% EBITDA on an ex-recovery basis with no incremental pledge disclosed; it slides to Lean Short / Avoid Ownership if margin prints ≤8% (especially with recoveries still flowing above the line) or any new pledge appears. Until that print lands, paying 97x trailing for a binary that resolves within weeks does not earn the wait.